What one share of BioLineRx holds
We are a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. Our first approved product, APHEXDA® (motixafortide), a novel peptide for the treatment of stem-cell mobilization and solid tumors, with an indication in the United States for stem cell mobilization for autologous transplantation in multiple myeloma, is being developed and commercialized by Ayrmid Pharma Ltd.
BioLineRx’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.29 |
|---|---|
| Profit | −$0.49 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.97 |
| Cash and investments | $0.75 |
| Book value | $4.18 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$168.07 | $31.32 | −$196.68 | — | $555.69 |
| 2016 | — | −$169.29 | $0.56 | −$155.65 | — | $374.32 |
| 2017 | — | −$162.40 | $2.25 | −$139.28 | — | $301.99 |
| 2018 | — | −$126.87 | $0.96 | −$134.62 | — | $215.71 |
| 2019 | — | −$104.28 | $0.27 | −$93.16 | — | $116.94 |
| 2020 | — | −$71.24 | $0.00 | −$55.07 | — | $37.86 |
| 2021 | $0.00 | −$24.49 | $0.09 | −$21.42 | — | $57.12 |
| 2022 | $0.00 | −$19.34 | $0.10 | −$20.44 | — | $33.05 |
| 2023 | $2.99 | −$37.75 | $0.07 | −$14.15 | — | $7.30 |
| 2025 | $0.29 | −$0.49 | $0.01 | −$1.97 | — | $4.18 |
Common questions about BioLineRx
How much does one share of BioLineRx earn?
Over its latest fiscal year, BioLineRx lost $0.49 for each share on $0.29 of sales.
Does BioLineRx pay a dividend?
BioLineRx didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is BioLineRx’s book value per share?
BioLineRx’s book value is $4.18 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of BioLineRx have?
Each share of BioLineRx has $0.75 of cash and investments, as of December 31, 2025.
What is BioLineRx’s free cash flow per share?
−$1.97 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has BioLineRx bought back shares?
BioLineRx’s share count rose about 4696% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.